title: Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane.
abstract: BACKGROUND
  Oxidative stress plays an important role in the pathogenesis of chronic liver diseases. The plasma level of 8-isoprostane, a product of lipid peroxidation, is a marker of oxidative stress in vivo. The aim of the present study was to clarify whether the degree of lipid peroxidation, as measured by the plasma level of 8-isoprostane, influences the progression of chronic liver diseases and hepatocarcinogenesis.
  
  
  METHODS
  Plasma 8-isoprostane levels were investigated in 14 patients with non-alcoholic fatty liver disease (NAFLD), 75 with chronic hepatitis C (CH-C), 14 with cured CH-C, 14 with HCV-positive hepatocellular carcinoma (HCC-C) and 38 healthy volunteers. 8-Isoprostane was measured by enzyme immunoassay after affinity column purification.
  
  
  RESULTS
  Plasma 8-isoprostane was significantly elevated in NAFLD (11.9 [3.8-56.8] pg/mL), CH-C (10.1 [4.2-134.5] pg/mL) as compared to controls (6.3 [3.6-11.1] pg/mL). Plasma 8-isoprostane values were positively correlated with body mass index in NAFLD (P < 0.05) and with total cholesterol in cured CH-C (P < 0.01). 8-Isoprostane levels were not significantly related to sex, age, biochemical data or iron metabolism markers in all liver diseases. In addition, after the administration of peg-interferon, the values of 8-isoprostane improved in almost all patients, reaching values of healthy subjects.
  
  
  CONCLUSIONS
  8-Isoprostane values are elevated in patients with NAFLD and CH-C as compared to healthy controls. Oxidative stress caused by increased lipid peroxidation is involved in the pathogenesis of NAFLD and CH-C.
authors.affiliation: Center for Physical and Mental Health, Mie University, Mie, Japan.
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Konishi
authors.forename: Motoh
authors.initials: M
authors.lastname: Iwasa
authors.forename: Jun
authors.initials: J
authors.lastname: Araki
authors.forename: Yoshinao
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Akira
authors.initials: A
authors.lastname: Katsuki
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Sumida
authors.forename: Naoki
authors.initials: N
authors.lastname: Nakagawa
authors.forename: Yuji
authors.initials: Y
authors.lastname: Kojima
authors.forename: Shozo
authors.initials: S
authors.lastname: Watanabe
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Adachi
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kaito
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000097:blood; D018450:Disease Progression; D004337:Drug Carriers; D005234:Fatty Liver / Q000097:blood* / Q000473:pathology; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D015227:Lipid Peroxidation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011379:Prognosis; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C075750:8-epi-prostaglandin F2alpha; D011092:Polyethylene Glycols; D015237:Dinoprost; C100416:peginterferon alfa-2a